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Abstract		26	
Type	 1	 diabetes	 is	 an	 autoimmune	 disease	 resulting	 from	 the	 destruction	 of	 pancreatic-β	27	
cells	by	the	immune	system	involving	innate	and	adaptive	immune	cells.	Mucosal-associated	28	
invariant	 T	 (MAIT)	 cells	 are	 innate-like	 T-cells	 recognizing	 bacterial	 riboflavin-precursor	29	
derivatives	presented	by	the	MHC-I	related	molecule,	MR1.	Since	T1D	is	associated	with	gut	30	
microbiota	modification,	we	 investigated	MAIT	cells	 in	 this	pathology.	 In	T1D	patients	and	31	
non-obese	 (NOD)	 diabetic	 mice,	 we	 detected	 MAIT	 cell	 alterations,	 including	 increased	32	
granzyme	B	production,	which	occur	before	disease	onset.	Analysis	of	NOD	mice	deficient	33	
for	MR1,	and	therefore	lacking	MAIT	cells,	revealed	a	loss	of	gut	integrity,	increased	anti-islet	34	
responses	 associated	with	 exacerbated	 diabetes.	 Altogether	 our	 data	 highlight	 the	 role	 of	35	
MAIT	 cells	 in	 the	 maintenance	 of	 gut	 integrity	 and	 the	 control	 of	 anti-islet	 autoimmune	36	
responses.	 MAIT	 cell	 monitoring	 could	 represent	 a	 new	 biomarker	 in	 T1D	 while	 their	37	
manipulation	may	open	new	therapeutic	strategies.	38	
	39	
	40	
Introduction	41	
Type	1	Diabetes	(T1D)	is	an	auto-immune	disease	characterized	by	the	selective	destruction	42	
of	 pancreatic	 islet	 β	 cells	 producing	 insulin,	 in	 the	 context	 of	 an	 underlying	 multigenetic	43	
inheritance
1
.	When	most	of	the	β	cells	are	destroyed	or	non-functional,	the	consecutive	lack	44	
of	insulin	results	in	hyperglycemia	and	requires	a	life-long	insulin	replacement	therapy
1
.	The	45	
physiopathology	 of	 T1D	 involves	 both	 innate	 and	 adaptive	 immune	 systems	 that	 are	46	
inappropriately	 activated	 inducing	 a	 loss	 of	 self-tolerance	 and	 islet	 destruction
2–5
.	 T1D	 is	47	
characterized	 by	 the	 presence	 of	 anti-islet	 autoantibodies	 and	 autoreactive	 T	 cells.	 Innate	48	
immune	cells	are	involved	at	various	stages	of	the	disease	and	are	particularly	important	for	49	
the	 initiation	 of	 the	 local	 immune	 response	 in	 the	 pancreas	 and	 the	 pancreatic	 lymph	50	
nodes
2,4.	 Recent	 data	 have	 highlighted	 the	 role	 of	 the	 intestinal	 microbiota	 in	 T1D	 by	51	
transfer	experiments	 in	NOD	mice
6–9
	 and	gut	microbiota	differences	 in	children	associated	52	
with	 T1D	 development
10–12
.	 Several	 studies	 also	 described	 gut	mucosa	 alterations	 in	NOD	53	
mice	and	T1D	patients
13–17
.	54	
MAIT	 cells	 are	 innate-like	 T	 cells	 recognizing	 bacterial	 metabolites,	 derived	 from	 the	55	
synthesis	 of	 riboflavin,	 presented	 by	 the	 monomorphic	 major-histocompatibility-complex-56	
3	
	
class-I-related	protein	MR1
18–20
.	These	non-conventional	T	cells	express	a	conserved	αβ-TCR,	57	
consisting	of	an	invariant	TCRα	chain,	Vα7.2-Jα33/20/12	in	humans	and	Vα19-Jα33	in	mice,	58	
with	 a	 restricted	 set	 of	 TCRβ	 chains.	MAIT	 cells	 produce	 various	 cytokines	 such	 as	 TNF-α,	59	
IFN-γ,	 IL-17	 and	 granzyme	 B	 (GzB)	 that	 could	 participate	 to	 tissue	 inflammation	 and	 cell	60	
death
18,21–31
.	 The	near	 absence	of	MAIT	 cells	 in	 germ-free	mice
18,32
	 and	 their	 physiological	61	
localization	 at	 mucosal	 sites	 including	 the	 gut
18,23
	 suggest	 a	 strong	 interaction	 with	 the	62	
microbiota.	Here	for	the	first	time	we	described	MAIT	cell	alteration	in	T1D	patients	and	our	63	
mouse	 data	 reveal	 the	 protective	 role	 of	MAIT	 cells	 against	 T1D.	 The	 localization	 and	 the	64	
function	of	MAIT	cells	highlight	 their	key	 role	 in	 the	maintenance	of	gut	 integrity,	 thereby	65	
controlling	the	development	of	autoimmune	responses	against	pancreatic	β	cells.	66	
	67	
	68	
Results	69	
Alteration	of	blood	MAIT	cell	frequency	and	phenotype	in	children	with	recent	onset	T1D	70	
We	first	began	the	investigation	of	MAIT	cells	 in	T1D	by	analyzing	MAIT	cell	frequency	and	71	
phenotype	 in	 fresh	 peripheral	 blood	 samples	 from	 children	 with	 recent	 onset	 T1D	 and	72	
children	with	established	T1D	as	compared	to	age-matched	control	children	(Supplementary	73	
Tables	 1	 and	 2).	 MAIT	 cells	 can	 be	 identified	 in	 human	 blood	 as	 CD4
-
	 T	 lymphocyte	74	
expressing	Vα7.2	TCRα	gene	segment	and	CD161high19,20,24,33,34	(Fig.	1a).	MAIT	cell	frequency	75	
and	number	was	decreased	 (3-fold)	 in	 the	blood	of	 recent	onset	T1D	children	whereas	no	76	
significant	 difference	 was	 observed	 in	 children	 with	 established	 disease	 as	 compared	 to	77	
control	children	(Fig.	1a	and	Supplementary	Fig.	1a).	Decreased	frequency	was	observed	in	78	
both	 CD8
+
	 and	 double	 negative	 (DN)	MAIT	 cell	 subsets	 (Supplementary	 Fig.	 1b).	 Of	 note	79	
there	 was	 no	 difference	 in	 the	 frequencies	 of	 conventional	 CD4	 and	 CD8	 T	 cells,	 and	 of	80	
Vα7.2
+
CD161
-
	T	cells	between	the	three	children	populations	confirming	that	the	decrease	of	81	
MAIT	 cell	 frequency	 at	 the	 onset	 of	 T1D	 was	 not	 secondary	 to	 changes	 in	 other	 T	 cell	82	
populations	 nor	 to	 down-regulation	 of	 the	 CD161	 marker	 (Supplementary	 Fig.	 2a-b).	83	
Analysis	 of	MAIT	 cell	 phenotype	 showed	 a	 decreased	 frequency	 of	MAIT	 cells	 expressing	84	
tissue	 recruitment/adhesion	 molecules	 (CCR6,	 CD56)	 at	 the	 onset	 of	 the	 disease,	 an	85	
increased	 frequency	of	MAIT	 cells	 expressing	 the	activation/exhaustion	markers	CD25	and	86	
PD1,	and	a	decreased	frequency	of	MAIT	cells	expressing	the	anti-apoptotic	molecule	Bcl-2	87	
(Fig.	 1b-c).	 Multi-parametric	 analysis	 of	 MAIT	 cells	 in	 the	 children	 with	 established	 T1D	88	
4	
	
highlighted	the	intermediate	phenotype	of	MAIT	cells	between	those	from	recent	onset	T1D	89	
and	control	children	 (Fig.	1c).	 Interestingly	 in	 recent	onset	children	 the	 frequency	of	MAIT	90	
cells	expressing	migratory	CCR6
+
	or	anti-apoptotic	Bcl-2	molecules	were	positively	correlated	91	
with	 the	 frequency	 of	 MAIT	 cells,	 whereas	 MAIT	 cell	 CD25	 expression	 was	 negatively	92	
correlated	 with	 MAIT	 cell	 frequency	 (Supplementary	 Fig.3).	 These	 data	 suggest	 that	93	
decreased	blood	MAIT	cell	frequency	could	reflect	their	migration	to	inflamed	tissues	and/or	94	
their	death	by	apoptosis	subsequent	to	their	activation.		95	
	96	
Alteration	of	blood	MAIT	cell	function	in	children	with	recent	onset	T1D	97	
Cytokine	and	GzB	production	by	fresh	blood	MAIT	cells	was	analyzed	after	PMA-ionomycin	98	
stimulation.	MAIT	 cells	 from	children	with	 recent	onset	 T1D	produced	 less	 IFN-γ,	whereas	99	
their	production	of	TNF-α,	 IL-4,	 and	GzB	was	 increased	as	 compared	with	MAIT	cells	 from	100	
control	children	(Fig.	2a-b).	Of	note,	among	these	effector	molecules	only	the	frequency	of	101	
GzB	correlated	with	the	frequency	of	MAIT	cells,	the	higher	GzB	production	was	observed	in	102	
patients	 with	 the	 lower	 frequency	 of	 MAIT	 cells	 (Supplementary	 Fig.4).	 Multi-parametric	103	
analysis	of	cytokines	and	GzB	production	by	MAIT	cells	also	showed	an	intermediate	status	104	
of	blood	MAIT	cells	from	children	with	established	T1D,	between	those	from	control	children	105	
and	 recent	 onset	 T1D	 children,	 as	 already	 observed	 for	MAIT	 cell	 surface	 phenotype	 (Fig.	106	
2b).	We	next	analyzed	the	ability	of	MAIT	cells	to	respond	to	specific	TCR	activation	by	the	107	
ligand	5-OP-RU
20
.	Upon	stimulation,	MAIT	cells	from	control	children	up-regulated	CD69	and	108	
CD25	activation	markers.	Addition	of	 blocking	MR1	mAb	 confirms	 that	 this	 activation	was	109	
TCR-dependent.	Interestingly,	MAIT	cell	activation	was	significantly	reduced	in	children	with	110	
recent	 onset	 T1D	 (Fig.	 2c).	 Together,	 these	 results	 highlight	 functional	 alteration	 of	MAIT	111	
cells	in	children	with	recent	onset	T1D.		112	
	113	
Cytotoxic	function	of	MAIT	cells	on	human	β	cells	114	
We	next	investigated	potential	links	between	phenotype	and	functional	alterations	of	MAIT	115	
cells	and	clinical	characteristics	of	children	with	recent	onset	T1D	(Supplementary	Tables	1	116	
and	2).	 Interestingly,	 the	 frequency	of	GzB
+
	MAIT	 cells	was	negatively	 associated	 (r=-0.71,	117	
P<0.0001)	with	children’s	age	at	diagnosis	(Fig.	3a),	which	is	in	agreement	with	the	current	118	
view	that	T1D	is	more	aggressive	in	the	youngest	children
35,36
.	We	speculate	that	production	119	
of	 GzB	 by	 MAIT	 cells,	 reflecting	 their	 cytotoxic	 potential,	 could	 be	 involved	 in	 the	120	
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physiopathology	of	T1D.	Other	MAIT	cell	parameters,	such	as	their	frequency,	CCR6	and	Bcl-121	
2	 expression,	 were	 also	 associated	 with	 the	 age	 at	 diagnosis	 (Supplementary	 Fig.	 5).	 No	122	
significant	 correlations	 between	MAIT	 cell	 parameters	 and	 age	were	 observed	 in	 controls	123	
and	 children	 with	 established	 T1D	 (data	 not	 shown).	 Production	 of	 GzB	 by	 MAIT	 cells	124	
inversely	 correlated	with	HbA1c	 level	 at	 the	onset	 of	 the	disease	but	 not	 in	 children	with	125	
established	T1D	(Fig.	3a).	Indeed,	a	more	aggressive	disease	associated	with	sustained	MAIT	126	
cell	abnormalities	suggests	a	shorter	time	of	hyperglycemia	before	the	onset	thereby	lower	127	
levels	of	HbA1c
36
.		128	
The	 strong	 inverse	 correlation	 between	GzB	 production	 by	MAIT	 cells	 and	 the	 age	 of	 the	129	
children	 at	 the	 time	 of	 onset	 suggested	 that	MAIT	 cells	 could	 participate	 to	 β-cell	 death.	130	
Interestingly,	 inflammatory	 cytokines	 usually	 produced	 in	 inflamed	 islets	 during	 T1D	131	
progression	 (IL1-β,	 IFN-γ	 and	 TNF-α)	 induce	MR1	 up-regulation	 on	 the	 human	 β-cell	 line,	132	
EndoC-βH1	cell	 (Fig.	3b).	Moreover,	co-culture	experiments	demonstrated	the	direct	killing	133	
of	EndoC-βH1	cells
37
	by	purified	MAIT	cells	from	four	healthy	donors.	Cell-sorted	MAIT	cells	134	
were	cultured	in	presence	of	IL-7,	then	co-cultured	with	Endo-βH1	cells	pre-incubated	with	135	
inflammatory	cytokines,	or	not.	The	data	in	Figure	3c-d	show	that	MAIT	cells	induced	MR1-136	
dependent	EndoC-βH1	cell	apoptosis	 (annexin	V
+
	PI
-
),	which	was	more	efficient	with	Endo-137	
βH1	 cells	 pre-incubated	 with	 inflammatory	 cytokines.	 During	 co-cultures	MAIT	 cells	 were	138	
activated	(CD25	up-regulation)	and	degranulated	(CD107a
+
)	(Fig.	3e).	Altogether	these	data	139	
suggest	that	in	the	inflamed	pancreas	during	diabetes	progression	MAIT	cells	can	participate	140	
to	β-cell	destruction.		141	
	142	
MAIT	cell	alterations	at	different	disease	stages		143	
To	further	explore	the	link	between	MAIT	cell	parameters	and	clinical	characteristics,	15	of	144	
the	 children	 with	 recent	 onset	 T1D	 were	 analyzed	 one	 year	 later.	 Although	 MAIT	 cell	145	
frequency	among	T	cells	remain	to	a	similar	 level	after	one	year	of	 insulin,	both	CCR6
+
	and	146	
Bcl-2
+
	 MAIT	 cell	 frequencies	 significantly	 increased.	 Conversely	 the	 frequencies	 of	 CD25
+
,	147	
PD1
+
,	 IL-17A
+
,	 and	 to	 some	 extent	 GzB
+
,	 MAIT	 cells	 decreased	 to	 levels	 observed	 in	 the	148	
control	 children	 (Fig.	 4a).	 This	 longitudinal	 analysis	 strengthened	 the	data	obtained	 in	 the	149	
transversal	analysis	 showing	 that	MAIT	cell	phenotype	was	more	similar	 to	controls	 in	 the	150	
children	under	insulin	therapy	than	at	disease	onset.		151	
6	
	
	152	
MAIT	cells	as	a	new	biomarker	of	T1D	153	
Canonical	analysis	was	performed	 to	compare	MAIT	cell	 alterations	 in	 the	 three	groups	of	154	
children	(controls,	 recent	onset	and	established	T1D).	This	analysis	revealed	that	MAIT	cell	155	
parameters	were	sufficient	 to	discriminate	 the	 three	groups	of	children	analyzed	 (Fig.	4b).	156	
Parameters	involved	in	this	discrimination	are	shown	in	supplementary	Figure	6.	Moreover,	157	
a	statistical	regression	analysis	identified	four	surface	markers	(CCR6,	CD25,	PD1,	CD56)	that	158	
define	a	predictive	model	for	the	diagnosis	of	the	disease	tested	on	the	ROC	curve	(Fig.	4c).		159	
Importantly,	we	 confirmed	 in	 another	 cohort	 of	 children	 from	Milano	 that	 frequency	 and	160	
phenotype	alteration	of	MAIT	 cell	was	observed	 in	 recent	onset	T1D	as	 compared	 to	age-161	
matched	 control	 children	 (Supplementary	 Table	 3	 and	 supplementary	 Fig.	 7).	 However	162	
technical	difficulties	impacting	CD56	analysis	on	these	frozen	cells	did	not	allow	to	applying	163	
the	predictive	model.	164	
Finally,	 to	 test	 whether	 MAIT	 cell	 alterations	 could	 be	 detected	 before	 the	 onset	 of	165	
diagnosis,	 we	 characterized	MAIT	 cells	 in	 adults	 at	 risk	 to	 develop	 T1D	 defined	 as	 direct	166	
relatives	of	T1D	patients	with	at	least	two	positive	autoantibodies	(Supplementary	Table	4).	167	
As	 compared	 to	 the	 control	 group,	 there	 were	 increased	 frequencies	 of	 CD25
+
	 and	 PD1
+
	168	
MAIT	cells	and	a	trend	toward	a	lower	CCR6
+
	MAIT	cell	frequency,	even	though	the	number	169	
of	 individuals	analyzed	were	 limited	 (Fig.	4d).	Altogether	our	data	 in	patients	 suggest	 that	170	
MAIT	cells	represent	a	new	biomarker	in	T1D	and	they	could	play	a	role	in	the	pathogenesis	171	
of	 T1D.	 Therefore,	 we	 investigated	 MAIT	 cells	 in	 mouse	 models,	 which	 allow	 analysis	 in	172	
tissues	at	different	stages	of	disease	development	and	could	be	manipulated	to	determine	173	
whether	MAIT	cells	are	involved	in	T1D	physiopathology.	174	
	175	
MAIT	cell	characterization	in	NOD	mice	176	
The	NOD	mouse	is	the	most	studied	animal	model	of	T1D	because	it	shares	many	features	177	
with	 the	 human	disease
3,4
,	 thus	we	 investigated	whether	 any	 of	 the	MAIT	 cell	 alterations	178	
observed	 in	T1D	patients	were	evident	 in	 this	model.	MAIT	cells	were	characterized,	 in	10	179	
week-old	NOD	 and	 C57BL/6	mice,	 using	mouse-MR1	 tetramers	 loaded	with	 the	 riboflavin	180	
derivative	 5-OP-RU,	 whereas	 control	 tetramers	 were	 loaded	 with	 the	 non-agonist	 folate	181	
derivative	Ac-6-FP
20,27,32,38
	(Fig.	5a).	The	frequency	and	absolute	number	of	MAIT	cells	were	182	
lower	in	NOD	than	C57BL/6	mice;	3	to	10-fold	lower	in	spleen	and	pancreatic	lymph	nodes	183	
7	
	
(PLN).	However	MAIT	 cells	were	 present	 in	 pancreatic	 islets	 of	NOD	mice	 and	were	more	184	
abundant	 in	 the	 ileum	of	NOD	 than	C57BL/6	mice	 (Fig.	5b).	Of	note	 circulating	MAIT	 cells	185	
were	below	detection	limit	in	the	blood	from	NOD	mice.	Mouse	MAIT	cells	can	be	divided	in	186	
three	subsets,	CD4
+
,	CD8
+
	or	DN
38
	(Fig.	5c-d).	As	previously	shown,	MAIT	cells	in	peripheral	187	
tissues	of	C57BL/6	mice	were	mainly	DN	and	expressed	CD44		(Fig.	5d	supplementary	Fig.	8),	188	
corresponding	 to	 functionally	mature	MAIT	cells
32
.	 In	contrast,	 the	proportion	of	DN	MAIT	189	
cells	was	lower	in	NOD	than	C57BL/6	mice	(Fig.	5c-d).	Analysis	of	activation	markers	on	MAIT	190	
cells	from	NOD	mice	revealed	that	CD69	was	highly	expressed	in	pancreatic	islets	and	ileum,	191	
and	CD25	was	elevated	in	PLN	and	islets	(Fig.	5e-f).	While	CD69	was	also	elevated	on	ileum	192	
MAIT	cells	from	C57BL/6	mice,	CD25	was	not	up-regulated	in	PLN	from	C57BL/6	mice	(Fig.	5f	193	
and	supplementary	Fig.	9).	Of	note	CD44	was	more	expressed	on	ileal	MAIT	cells	from	NOD	194	
than	C57BL/6	mice.	Regarding	cytokine	production	in	NOD	mice,	in	all	tissues	MAIT	cells	are	195	
strong	 producers	 of	 IL-17A	 and	 TNF-α,	whereas	 IFN-γ	 and	 IL-22	was	 detected	 in	 only	 few	196	
cells	 (Fig.	5g-h	and	supplementary	Fig.	10).	Moreover,	a	majority	of	MAIT	cells	 in	PLN	and	197	
ileum	 from	 NOD	 mice	 express	 CD44	 and	 they	 produce	 large	 amount	 of	 cytokines.	198	
Interestingly,	similar	results	were	obtained	for	TNF-α,	IFN-γ	and	IL-22	cytokine	production	in	199	
both	C57BL/6	and	NOD	mice	(Fig.	5h	and	supplementary	Fig.	11).	Of	note,	higher	frequency	200	
of	 MAIT	 cells	 from	 NOD	 produce	 IL-17,	 compare	 to	 C57BL/6,	 which	 could	 contribute	 to	201	
inflammation	and	diabetes	progression.		As	in	C57BL/6	mice
34,38,39
,	most	MAIT	cells	in	NOD	202	
mice	express	PLZF,	ROR-γt	and	T-bet,	transcription	factors	characteristic	of	this	innate-like	T	203	
cell	lineage
23
	(supplementary	Fig.	12).	Altogether	these	data	show	that	spleen	MAIT	cells	are	204	
less	frequent	and	mature	in	NOD	than	in	C57BL/6	mice,	however	they	express	an	activated	205	
phenotype	and	produce	cytokines	in	PLN,	islets	and	ileum	from	NOD	mice.	206	
	207	
MAIT	cell	accumulation	and	dual	function	during	diabetes	development	in	NOD	mice	208	
We	next	 analyzed	MAIT	 cells	 in	NOD	mice,	 at	 three	 stages	 of	 disease	 development,	 early	209	
stage	(6-7	weeks	old),	pre-diabetic	 (15-17	weeks	old)	and	mice	at	the	onset	of	the	disease	210	
(Fig.	6a).	These	 three	stages	correspond	respectively	 to	mild	peri-insulitis	 characterized	by	211	
moderate	infiltration	of	inflammatory	cells	around	pancreatic	islets,	to	insulitis	associated	to	212	
partial	 β-cell	 destruction	 and	 to	 severe	 destructive	 insulitis	 resulting	 in	 insufficient	 insulin	213	
production
4,5
	and	hyperglycemia.	During	disease	progression,	MAIT	cell	frequency	increased	214	
8	
	
in	 pancreatic	 islets	 and	 transiently	 in	 spleen	 and	 ileum	 (Fig.	 6a).	 These	 data	 show	 that	215	
disease	progression	is	associated	to	modification	of	MAIT	cell	tissue	distribution.	Since	MAIT	216	
cells	are	effector	cells	and	can	migrate	to	 inflamed	tissues,	we	analyzed	their	migration	by	217	
transfer	experiments.	MAIT	cells	were	transferred	into	congenic	NOD	mice	at	two	stages	of	218	
disease	 development.	 Interestingly	 there	 is	 a	 higher	 recruitment	 of	 MAIT	 cells	 in	 the	219	
pancreas	 of	 20-25	 week	 old	 NOD	 mice	 than	 in	 younger	 (8-10	 week)	 mice	 (Fig.	 6	 b).	 In	220	
contrast,	 MAIT	 cell	 recruitment	 in	 ileum	 decreased	 with	 aging,	 supporting	 the	 decreased	221	
frequency	of	MAIT	cells	in	this	tissue	in	diabetic	NOD	mice.			222	
To	further	explore	the	function	of	MAIT	cells	in	T1D,	their	cytokine	production	was	analyzed	223	
in	various	tissues	at	the	three	stages	of	disease	development.	For	that	purpose,	MAIT	cells	224	
were	purified	by	cell-sorter	after	MR1-tetramer	staining,	and	level	of	GzB,	IFN-γ,	IL-17A	and	225	
IL-22	mRNA	was	analyzed	by	RT-qPCR	(Fig.	6c-d).	Interestingly,	in	pancreatic	islets	and	ileum,	226	
MAIT	cell	cytokine	profiles	evolved	with	disease	progression.	In	islets,	MAIT	cell	production	227	
of	IFN-γ	was	detected	in	diabetic	mice,	and	GzB	was	already	detectable	at	pre-diabetic	stage	228	
and	 further	 increased	 in	diabetic	mice	 (Fig.	6c).	Both	GzB	and	 IFN-γ	 from	MAIT	cells	 could	229	
participate	to	pancreatic	β-cell	death4.	This	 increased	production	of	 IFN-γ	and	GzB	 in	 islets	230	
was	 confirmed	at	protein	 levels	 (Fig.	 6e).	 In	 ileum	 from	NOD	mice,	 T1D	development	was	231	
associated	with	decreased	level	of	IL-17A	and	IL-22	mRNA	in	MAIT	cells	at	the	diabetic	stage	232	
(Fig.	6d).	Diminished	IL-17A	and	IL-22	production	by	ileal	MAIT	cells	from	diabetic	NOD	mice	233	
was	confirmed	by	intra-cellular	staining	(Fig.	6f).	Altogether	these	results	suggest	that	MAIT	234	
cells	could	play	a	dual	role	in	NOD	mice	according	to	their	tissue	localization,	promoting	β-235	
cell	death	in	the	pancreas	whereas	participating	in	gut	mucosa	homeostasis.	236	
	237	
Gut	mucosa	alterations	during	T1D	progression	in	NOD	mice		238	
Since	 ROR-γt	 is	 the	 master	 transcription	 factor	 for	 IL-17A40	 and	 is	 involved	 in	 IL-22	239	
production
41,42
,	we	analyzed	ROR-γt	expression	in	MAIT	cells	in	the	ileum	of	ROR-γt-GFP	NOD	240	
mice	(Fig.	7a).	According	to	the	decreased	level	of	IL-17A	and	IL-22	in	diabetic	mice,	ROR-γt	241	
expression	was	also	impacted	at	the	onset	of	the	disease.	Decreased	IL-17,	IL-22	and	ROR-γt	242	
expression	by	MAIT	cells	in	diabetic	NOD	mice	prompt	us	to	analyze	IL-23	expression,	a	key	243	
cytokine	 inducing	 the	 production	 of	 these	 cytokines.	 Interestingly,	 at	 diabetes	 onset	 IL-23	244	
transcript	 level	 was	 decreased	 in	 the	 ileum	 (Fig.	 7b),	 which	 could	 contribute	 to	 the	245	
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decreased	IL-17/IL-22	production	by	MAIT	cells.	Of	note,	this	defect	in	cytokine	production	is	246	
associated	with	significant	 increased	gut	permeability,	as	measured	by	 in	vivo	FITC-dextran	247	
assay	(Fig.	7c).		248	
To	 investigate	 whether	 gut	 microbiota	 could	 directly	 impact	 MAIT	 cell	 function,	 we	249	
measured	at	different	stages	of	disease	development	the	level	of	bacterial	agonist	ligand	in	250	
intestinal	 content	 using	 an	 in	 vitro	 biological	 assay	 (Fig.	 7d-g).	 Intestinal	 contents	 activate	251	
purified	MAIT	cells	is	a	dose	dependent	manner,	as	5-OP-RU	positive	control	(Fig.	7d-e).	This	252	
activation	 was	 MR1	 specific	 since	 it	 was	 inhibited	 by	 the	 addition	 of	 Ac-6-FP	 antagonist	253	
ligand	 (Fig.	 7d-f).	MAIT	 cell	 activation	 by	 intestinal	 contents	 from	 young,	 pre-diabetic	 and	254	
diabetic	NOD	mice	did	not	reveal	significant	modification	of	MAIT	cell	 ligand	concentration	255	
(Fig.	7g).	Altogether,	these	data	suggest	that	MAIT	cell	defective	IL-17	and	IL-22	production	256	
might	 be	 due	 to	 lower	 IL-23	 level	 in	 diabetic	 mice	 in	 association	 to	 increased	 gut	257	
permeability.		258	
	259	
Absence	of	MAIT	cells	impacts	diabetes	development	and	intestinal	homeostasis.	260	
To	determine	the	role	of	MAIT	cells	 in	the	pathogenesis	of	T1D,	we	generated	MR1
-/-
	NOD	261	
mice,	since	MR1	is	required	for	thymic	development	of	MAIT	cells
18,32,33,43
.	Our	analysis	was	262	
performed	 on	MR1
-/-
	 and	MR1
+/-
	 littermate	 NOD	mice	 in	 co-housed	 condition	 to	 exclude	263	
possible	 impact	of	different	gut	microbiota	on	MAIT	cell	 function.	As	expected	MR1
-/-
	NOD	264	
mice	 lacked	MAIT	 cells,	whereas	 there	were	no	 significant	differences	 in	 the	 frequency	of	265	
Foxp3
+
	 CD4	 Treg,	 iNKT	 and	 γδT	 cells	 in	 the	 spleen	 and	 PLN	 from	 both	 lines	 (Fig.	 8a	 and	266	
supplementary	 Fig.	 13).	 Most	 interestingly,	 MR1
-/-
	 NOD	 mice	 developed	 exacerbated	267	
diabetes	 compared	 to	 their	 littermate	MR1
+/-
	 controls	 indicating	a	protective	 role	of	MAIT	268	
cells	 in	T1D	development	 (Fig.	8b).	Of	note,	we	also	observed	 the	protective	 role	of	MAIT	269	
cells	against	T1D	using	multi-low	dose	streptozotocin	treatment,	commonly	used	to	induce	270	
T1D	 in	 C57BL/6	mice
44
.	 As	 shown	 in	 the	 supplementary	 Fig.	 14,	 MR1
-/-	
B6-MAIT
CAST	
mice	271	
were	 more	 susceptible	 to	 T1D	 development	 than	 their	 MR1
+/-
	 B6-MAIT
CAST	
littermates.	272	
Corroborating	 incidence	results	 in	NOD	mice,	there	was	an	elevated	frequency	of	anti-islet	273	
CD8
+
	T	cells	specific	for	islet-specific	glucose-6-phosphatase	catalytic	subunit-related	protein	274	
(IGRP)
45
	and	IFN-γ+	anti-IGRP	CD8	T	cells,	respectively	in	the	PLN	and	pancreatic	islets,	from	275	
MR1
-/-
	NOD	mice	compared	to	their	littermate	controls	(Fig.	8c-d).	Since	PLN	dendritic	cells	276	
(DC)	play	a	key	role	in	anti-islet	T	cell	priming
46,47
,	DC	phenotype	was	analyzed	in	both	lines	277	
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of	NOD	mice.	 Supporting	 increased	anti-islet	T	 cell	 response,	CD11c
+
CD11b
+
CD103
+	
DC
48–50
	278	
frequency	was	elevated	in	PLN	from	MR1
-/-	
NOD	mice	and	these	DC	expressed	higher	level	of	279	
MHC	class	 II	molecules	and	CD86	reflecting	 their	more	activated	status	 (Fig.	8e).	Since	gut	280	
mucosa	 integrity	 controls	 immune	 cell	 activation
44,51,52
	 and	 MAIT	 cells	 are	 abundant	 and	281	
activated	in	this	tissue,	we	explored	gut	mucosa	of	MR1
-/-
	NOD	mice.	The	lack	of	MAIT	cells	282	
resulted	in	a	significant	 increased	intestinal	permeability	evaluated	by	FITC-dextran	level	 in	283	
the	 blood	 after	 oral	 gavage	 (Fig.	 8f).	 Reduced	mRNA	 expression	 of	 occludin	 and	mucin-2	284	
confirmed	defective	gut	epithelial	cell	 function	and	histology	analysis	showed	an	abnormal	285	
mucus	accumulation	in	goblet	cells	of	MR1
-/-
	NOD	mice	(Fig.	8g-h).	These	abnormalities	were	286	
associated	with	increased	lymphoid	cell	infiltration	in	the	lamina	propria	(Fig.	8i).	Regarding	287	
the	role	of	MAIT	cells	 in	 the	control	of	gut	 integrity	and	DC	priming	 in	 the	PLN,	significant	288	
increased	 level	 of	 bacterial	 DNA	 16S	 was	 detected	 in	 the	 PLN	 of	 MR1
-/-
	 versus	 control	289	
littermates	(Fig.	8j).	Altogether,	our	data	reveal	a	 link	between	MAIT	cells,	the	gut	mucosa	290	
and	the	increased	anti-islet	T	cell	responses.		291	
	292	
	293	
Discussion	294	
This	 study	 reveals	MAIT	 cell	 alteration	 in	 T1D	 patients	 as	well	 as	 in	 NOD	mice.	MAIT	 cell	295	
frequency	 is	 lower	 in	 the	peripheral	blood	of	patients	 compared	 to	healthy	 children.	 Such	296	
decreased	 frequency	 could	 reflect	 their	 migration	 from	 the	 blood	 to	 inflamed	 tissues	 as	297	
described	 in	other	 inflammatory	and	autoimmune	diseases
24–26,29,53–55
	and	as	supported	by	298	
their	 increased	 frequency	 and	 migration	 in	 the	 pancreas	 of	 NOD	 mice	 during	 T1D	299	
development.	 Lower	 frequency	 of	 blood	MAIT	 cells	 could	 also	 result	 from	 their	 sustained	300	
activation	leading	to	cell	exhaustion	as	indicated	by	their	expression	of	Bcl-2,	CD25	and	PD1	301	
and	 by	 their	 defective	 in	 vitro	 response	 to	 Ag	 specific	 stimulation,	 in	 contrast	 to	 their	302	
increased	cytokines	and	GzB	production	upon	PMA-ionomycin.	Of	note	MAIT	cell	defect	 in	303	
T1D	 might	 not	 only	 be	 a	 consequence	 of	 diabetes	 development	 but	 also	 might	 reflect	304	
intrinsic	differences.	Indeed	in	NOD	mice,	as	compared	to	C57BL/6	mice,	MAIT	cells	are	less	305	
frequent	and	express	a	less	mature	phenotype,	based	on	CD44	expression.		306	
Our	 study	 in	 NOD	 mice	 points	 out	 the	 different	 phenotype	 and	 function	 of	 MAIT	 cells	307	
according	 to	 their	 tissue	 localization.	 This	 heterogeneity	 of	 MAIT	 cells	 observed	 in	 mice	308	
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might	 explain	 the	 mosaic	 of	 MAIT	 cell	 populations	 detected	 in	 the	 blood	 from	 control	309	
individuals	and	T1D	patients.	It	would	be	interesting	to	further	investigate	the	recirculation	310	
of	MAIT	cells	between	peripheral	tissues	and	the	blood.	However	study	of	blood	MAIT	cells	311	
in	NOD	mice	was	not	performed	due	to	their	extremely	low	frequency.		312	
The	 analysis	 of	 peripheral	 tissues	 from	NOD	mice	 highlights	 the	 role	 of	MAIT	 cells	 in	 two	313	
tissues,	 the	 pancreas	 and	 the	 gut	mucosa.	 In	 the	 pancreas,	 not	 only	MAIT	 cell	 frequency	314	
increased	 with	 diabetes	 development	 but	 also	 their	 production	 of	 GzB	 and	 IFN-γ,	 which	315	
could	participate	to	the	destruction	of	β-cells
4,5
.	Most	interestingly,	in	the	youngest	children	316	
with	recent	onset	T1D,	usually	associated	to	a	more	aggressive	disease
35,36
,	circulating	MAIT	317	
cells	 express	 the	 highest	 level	 of	 GzB.	 This	 parameter	 has	 the	 strongest	 correlations	with	318	
clinical	characteristics,	age	at	diagnosis	and	%	of	HbA1c.	Of	note,	increased	GzB	production	319	
was	 not	 observed	 in	 other	 T	 cell	 populations	 (data	 not	 shown).	 Moreover	 co-culture	320	
experiments	show	that	MAIT	cells	are	able	to	directly	kill	human	β	cell	line.		321	
In	 contrast	 to	 the	 pancreas,	 in	 the	 gut	 mucosa	 MAIT	 cells	 might	 play	 a	 protective	 role	322	
through	 their	 production	 of	 IL-17A	 and	 IL-22,	 two	 key	 cytokines	 in	 intestinal	323	
homeostasis
41,42,56,57
.	 The	 presence	 of	 gut	 alterations	 as	 T1D	 progress	 in	 NOD	 mice	324	
underscores	the	importance	of	MAIT	cells	in	maintaining	gut	mucosa	homeostasis.	Moreover	325	
the	lack	of	MAIT	cells	in	MR1
-/-
	NOD	mice	is	associated	with	a	loss	of	gut	integrity	shown	by	326	
FITC-dextran	 assay,	 decreased	 expression	 of	 tight	 junction	 proteins	 and	 abnormal	 mucus	327	
distribution.	 Absence	 of	 MAIT	 cells	 in	 NOD	 mice	 favors	 gut	 leakiness,	 associated	 with	328	
translocation	of	bacteria	components,	such	as	16S	bacterial	DNA,	from	the	gut	to	peripheral	329	
tissues.	 The	 presence	 of	 bacterial	 DNA	 could	 promote	 T1D	 development	 through	 DC	330	
activation	 via	 TLR	 receptors	 in	 PLN	 and	 increased	 anti-islet	 pathogenic	 T	 cell	 responses.	331	
Altogether,	our	data	support	the	model	in	which	MAIT	cell	deficiency	aggravates	gut	mucosa	332	
alterations,	 thereby	 promoting	 T1D	 development.	 These	 data	 are	 reminiscent	 of	 recent	333	
reports	 showing	 a	 critical	 link	 between	 the	 gut	 mucosa	 and	 the	 development	 of	334	
inflammatory	and	autoimmune	diseases	including	T1D
44,51,52
.	MAIT	cells	could	act	as	a	sensor	335	
of	environmental	changes	by	responding	to	alteration	of	gut	mucosa	by	modulating	the	host	336	
immune	system.	Their	abundance	and	activation	status	 (CD69,	cytokine	production)	 in	 the	337	
gut	 could	 explain	 the	 prominent	 regulatory	 role	 of	MAIT	 cells	 in	 the	 intestinal	mucosa	 of	338	
NOD	mice.		339	
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Overall	the	present	study	reveals	MAIT	cell	alteration	in	T1D	patients	as	well	as	in	NOD	mice	340	
and	highlights	the	protective	role	of	MAIT	cells	against	diabetes,	despite	their	infiltration	in	341	
the	 pancreas	 of	 NOD	mice	 and	 their	 production	 of	 GzB	 and	 IFN-γ.	 These	 data	 lead	 us	 to	342	
propose	 that	MAIT	 cells	 are	at	 the	 crossroad	between	gut	mucosa,	 inflammation	and	T1D	343	
(supplementary	 Fig.	 15).	 Interestingly,	MAIT	 cell	 alteration	 in	 both	 patients	 and	mice	 has	344	
been	detected	before	the	onset	of	diabetes,	indicating	that	MAIT	cell	could	represent	a	new	345	
biomarker	of	T1D	development.	Moreover,	our	data	suggesting	the	protective	role	of	MAIT	346	
cells	in	NOD	mice	at	the	level	of	the	gut	mucosa	could	pave	the	way	for	the	development	of	347	
new	 therapeutic	 strategies	 based	 on	 their	 local	 triggering	 in	 this	 tissue	 at	 early	 phase	 of	348	
disease	development.		 	349	
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Online	Methods		510	
Human	 samples.	 Peripheral	 blood	 samples	were	obtained	 from	control	 children	 and	 from	511	
T1D	children	admitted	in	the	Pediatric	Endocrinology	department	of	Necker	hospital,	Paris,	512	
France	 at	 T1D	 onset	 (i.e.	 within	 10	 days	 from	 first	 insulin	 injection),	 or	 with	 established	513	
disease.	All	control	children,	were	children	presenting	at	the	hospital	for	growth	retardation,	514	
short	 stature	 or	 precocious	 puberty.	 None	 of	 them	 had	 any	 other	 medical	 conditions	 or	515	
history	 of	 autoimmune	 disease.	 Patients	 with	 growth	 retardation	 or	 short	 stature	 were	516	
admitted	for	a	growth	hormone	stimulation	test.	All	of	 them	were	previously	screened	for	517	
coeliac	 disease	 or	 autoimmune	 thyroiditis	 that	 can	 be	 an	 etiology	 of	 short	 stature.	 This	518	
screening	was	negative	for	all	patients.	All	of	these	“control”	children	were	diagnosed	with	519	
idiopathic	growth	hormone	deficiency	or	 idiopathic	short	stature.	Patients	with	precocious	520	
puberty	 didn't	 have	 either	 any	 story	 of	 autoimmune	 disease.	 They	 were	 admitted	 for	 a	521	
gonadotropin-releasing	 hormone	 stimulation	 test	 and	 were	 diagnosed	 with	 idiopathic	522	
central	precocious	puberty.	As	 reported	 in	 the	method	section,	all	 "control"	patients	were	523	
screened	 for	 T1D	 related	 antibodies	 that	 were	 negative.	 Non-inclusion	 clinical	 following	524	
parameters	 contain:	 infection	 during	 the	 admission	 and	 associated	 other	 autoimmune	525	
diseases.	 The	 Ethics	 Committee	 (Comité	 de	 protection	 des	 personnes	 (CPP)	 Ile-de-France)	526	
approved	the	clinical	investigations	and	written	informed	consent	was	obtained	from	all	the	527	
parents.	For	the	Milan	cohort,	peripheral	blood	from	healthy	control	subjects	and	patients	at	528	
T1D	 onset	 (i.e.,	 within	 10	 days	 from	 first	 insulin	 injection)	were	 collected.	 The	 study	was	529	
approved	by	the	San	Raffaele	Hospital	Ethic	Committee	(protocol:	DRI-003).	At	risk	subjects	530	
were	enrolled	in	the	Type	1	Diabetes	TrialNet	Pathway	to	Prevention	Trial	(TN01	trial,	former	531	
TrialNet	Natural	History	Study)
58,59
	.	The	overall	objective	of	this	study	is	to	perform	baseline	532	
and	repeated	assessments	over	time	of	the	immunologic	and	metabolic	status	of	individuals	533	
who	are	at	risk	for	T1D	(first/second	degree	relatives	of	patients	with	T1D).	The	study	was	534	
approved	 by	 the	 San	 Raffaele	 Hospital	 Ethics	 Committee	 (protocol:	 NHPROTOCOL32803	535	
TN01).	 Our	 local	 study	 was	 approved	 by	 the	 TrialNet	 Ancillary	 Studies	 Subcommittee.	 All	536	
subjects	included	in	this	study	signed	the	informed	consent	prior	to	blood	donation.	537	
	 	538	
Mice.	MR1-/+	NOD	mice	was	generated	by	backcrosses	 (>15	times)	of	MR1
-/-
	C57BL/6J
18,33
	539	
on	 the	 NOD	 background,	 17	 insulin-dependent	 diabetes	 (Idd)	 loci	 associated	 with	540	
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susceptibility	 to	 T1D	 have	 been	 checked	 on	 all	 chromosomes.	 MR1
-/-
	 NOD	 mice	 were	541	
generated	by	 intercross	of	MR1
-/+
	NOD	mice	and	the	analyses	were	performed	with	MR1
-/-	
542	
and	MR1
-/+
	 NOD	 littermates	 kept	 in	 co-housed	 cages.	 Transgenic	 ROR-γt-GFP	NOD	mouse	543	
was	 generated	 by	 microinjection	 of	 ROR-γt-GFP	 BAC	 construct
60
	 into	 NOD	 embryos.	 B6-544	
MAIT
CAST	
mice	were	provided	by	O.	Lantz
39
.	All	mice	were	bred	under	speciﬁc	pathogen-free	545	
conditions	and	the	study	was	performed	on	females,	except	the	steptozotocin	experiments.	546	
NOD	mice	were	tested	weekly	(daily	in	steptozotocin	experiments)	and	considered	diabetic	547	
after	two	consecutive	positive	urine	glucose	tests	(DIABUR-TEST	5000,	Roche),	conﬁrmed	by	548	
a	 glycemia	 >	 200	 mg/Dl	 (ACCU-CHEK,	 Roche).	 This	 study	 was	 approved	 by	 the	 ethics	549	
committee	on	animal	experimentation	CEEA	34	(APAFIS	N°2015102016444419).	550	
	551	
Cell	 preparations.	Human	peripheral	 blood	mono-nucleated	 cells	 (PBMC)	of	 patients	 from	552	
Necker	 Hospital	 were	 isolated	 from	 fresh	 blood	 samples	 by	 Ficoll-Paque	 (Leucosep)	 or	553	
samples	from	San	Raffaele	hospital	were	defrosted	in	RPMI	with	10%	FCS	(Fetal	Cow	Serum).	554	
Mouse	cells	were	prepared	from	different	tissues	as	described	below.	For	Pancreatic	 islets	555	
isolation,	 mice	 were	 sacriﬁced	 and	 pancreas	 was	 perfused	 with	 3	 mL	 of	 a	 collagenase	 P	556	
solution	(0.8	mg/mL,	Roche),	which	was	then	isolated	and	set	free	from	surrounding	tissues	557	
and	 lymph	 nodes.	 Digestion	 of	 the	 pancreas	 was	 performed	 at	 37°C	 for	 10	min	 and	 was	558	
stopped	by	adding	 large	volume	of	cold	5%	FCS	RPMI	before	extensive	washes.	Pancreatic	559	
islets	 were	 then	 puriﬁed	 on	 a	 Ficoll	 discontinuous	 gradient.	 For	 immunoﬂuorescence	560	
analysis,	islets	were	dissociated	with	a	non-enzymatic	cell-dissociation	solution	(Sigma).	For	561	
Intestine	 cell	 isolation,	 Miltenyi	 Lamina	 Propria	 Dissociation	 Kit	 for	 mouse	 was	 used	 to	562	
prepare	epithelial	and	lamina	propria	cells.	Mice	were	sacriﬁced	and	intestine	was	removed	563	
from	mice.	Intestine	was	cleared	of	feces,	fat	tissue	and	Peyer’s	patches	with	HBSS	without	564	
Ca
2+
	and	Mg
2+
	 containing	10	mM	HEPES	solution.	After	passage	through	100	μm	filter,	 the	565	
cell	 suspension	was	 subjected	 to	Percoll	 (GE	Healthcare)	density	gradient	of	40%	and	80%	566	
and	the	interface	between	the	layers	containing	lamina	propria	lymphocytes	were	collected	567	
and	 suspended	 in	 PBS	 containing	 2%	 FCS	 and	 0.1%	 sodium	 azide.	 For	 the	 preparation	 of	568	
mouse	dendritic	 cells	 from	 lymph	nodes	and	 spleen,	mice	were	 sacriﬁced	and	organ	were	569	
cut	 in	 small	 pieces	 and	 then	digested	 at	 37°C	 for	 30	min	with	 2	mL	of	 collagenase	D	 (1.0	570	
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mg/mL,	 Roche)	 solution.	 Digestion	was	 stopped	 by	 adding	 a	 large	 volume	 of	 cold	 5%	 FCS	571	
RPMI,	and	cells	were	washed	and	filtered	on	cell	strainer	(40	µm,	BD	Falcon)	before	staining.	572	
	573	
Flow	 cytometry	 and	 antibodies.	 Cells	 were	 stained	 in	 PBS	 containing	 5%	 FCS	 and	 0.1%	574	
sodium	 azide.	 For	 human	 PBMC	 the	 following	 antibodies	 were	 used:	 CD3	 (OKT3),	 CD4	575	
(OKT4),	Vα7.2	(3C10),	CD161	(HP-3G10),	CCR6	(G034E3),	CD56	(HCD56),	CD69	(FN50),	Bcl-2	576	
(100),	IFN-γ	(4S	B3),	IL-17A	(BL168),	TNF-α	(MAb11)	and	MR1	(26.5)	mAbs	from	BioLegend;	577	
CD8	(SK1),	PD1	(MIH4),	CD25	(M-A251),	IL-4	(8D4-8),	granzyme	B	(GB11)	mAbs	and	CD107a	578	
(HYA3)	from	BD	Biosciences;	CD3	(REA),	CD161	(REA)	mAbs	from	Miltenyi	and	CD4	(RPA-T4)	579	
mAb	from	eBiosciences.	According	to	the	PBCM	number	obtained	from	each	patient,	surface	580	
staining	 was	 always	 performed,	 and	 when	 possible	 due	 to	 the	 number	 of	 PBMC	581	
intracytoplasmic	 staining	 of	 cytokines	 and	 GzB	 after	 PMA-ionomycin	 stimulation	 was	582	
analyzed,	 and	 then	 PBMC	 bcl-2	 expression	 was	 analyzed	 by	 intracytoplasmic	 staining	583	
(without	 stimulation).	 Data	 acquisition	 was	 performed	 using	 BD	 Biosciences	 LSR-Fortessa	584	
cytometer	 or	 FACS	 ARIA	 III	 cytometer	 for	 cells	 from	 patients	 from	 Necker	 hospital	 and	585	
Beckman	Coulter	Gallios	for	cells	from	patients	from	San	Raffaele	hospital.		586	
Staining	 of	 mouse	 cells	 was	 performed	 with	 the	 following	 antibodies:	 TCRβ	 (H57),	 TCR-587	
γδ (GL3),	CD45	(30F11),	CD8α (53−6.7),	CD103	(M290),	CD44	(IM7),	I-Ak	(10-3.6CD45),	CD86	588	
(GL1),	 IL-17A	 (TC11-18H10)	 and	 IFN-γ (XMG1.2) mAbs,	 were	 from	 BD	 Biosciences;	 CD19	589	
(6D5),	CD4	(GK1.5),	CD11b	(M1/70),	PLZF	(9E12),	T-bet	 (4B10),	CD25(PC61),	CD69	(HI-2F3),	590	
CD304	 (3E12),	 and	 CXCR3	 (SA011F11)	mAbs,	 were	 from	 Biolegend;	 CD11c	 (N418),	 CD170	591	
(1RNM44N),	F4/80	(BM8),	ROR-γt	(B2D)	and	FOXP3	(FJK-16s)	mAbs	were	from	eBioscience.	592	
Alpha-Galactosylceramide-CD1d	 tetramer	 was	 prepared	 by	 the	 laboratory	 and	 coupled	 to	593	
streptavidin-BV421	(Biolegend).	NRP-V7	tetramer	(IGRP206-214	(KYNKANVFL)	reactive	T	cell)	594	
and	 TUM	 tetramer	 (TUM	 (KYQAVTTTL)	 reactive	 T	 cell,	 were	 provided	 by	 the	 National	595	
Institutes	 of	Health	 tetramer	 core	 facility.	 Biotinylated	mouse	MR1	 tetramers	 loaded	with	596	
the	 active	 ligand	 (5-OP-RU)	 were	 used	 to	 specifically	 identify	MAIT	 cells	 and	 biotinylated	597	
MR1	tetramers	loaded	with	the	non-activating	ligand	6-formyl-pterin	(6-FP)	were	used	as	a	598	
negative	 control.	 MR1	 tetramers	 were	 coupled	 to	 streptavidin-PE	 (BD	 Biosciences)	 or	599	
Streptavidin-BV421	 (Biolegend)	 and	 cells	 were	 stained	 with	 tetramers	 for	 45	 min	 at	 RT	600	
before	surface	staining	with	mAbs.	Data	acquisition	was	performed	using	a	BD	Biosciences	601	
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LSRFortessa	or	FACS-ARIA	III	cytometer.	Flow	cytometric	analyses	were	performed	with	the	602	
FlowJo	analysis	software	V10.1	(Tree	Star)	and	the	Spice	software	V5.3	was	used	for	studying	603	
the	multiparametric	combination	of	cellular	staining.		604	
	605	
In	vitro	cell	stimulation.	For	ligand	stimulation	of	human	MAIT	cells,	5-OP-RU	solution	was	606	
obtained	 after	 incubating	 1	 molar	 equivalent	 of	 5-A-RU	 with	 2	 molar	 equivalent	 of	607	
methylglyoxal	 (Sigma-Aldrich).	Co-culture	of	Hela,	expressing	MR1	molecules,	and	PBMC	in	608	
media	 containing	 RPMI	 supplemented	 with	 10%	 FCS	 were	 done	 to	 analyze	 MAIT	 cell	609	
activation	from	both	controls	and	recent	onset	T1D	children	in	presence	of	MAIT	cell	ligand	610	
(5-OP-RU).	Briefly,	cells	were	plated	at	final	concentration	of	1	x	10
6	
PBMC/mL	and	1	x	10
6	
611	
Hela/mL	 (1:1	 ratio).	 In	 these	 cultures,	MAIT	 cells	were	 stimulated	O.N.	 by	 the	 addition	 of	612	
their	agonist	ligand	(5-OP-RU)	at	various	concentration	(0-5	nmol/L),	in	presence	of	blocking	613	
anti-MR1	(26.5	mAb)	or	not.	Then,	MAIT	were	stained	with	appropriate	antibodies	and	cell	614	
surface	activation	markers	were	analyzed	by	flow	cytometry.	615	
	616	
Intra-cellular	 staining.	 For	 human	 Bcl-2	 and	 mouse	 transcription	 factor	 staining,	 after	617	
surface	 staining	 lymphocytes	were	 resuspended	 in	 fixation/permeabilization	 buffer	 (Foxp3	618	
staining	kit	from	eBioscience)	and	incubated	at	4°C	in	the	dark	then,	cells	were	washed	with	619	
PERM	 Wash	 buffer	 (eBioscience)	 and	 labeled	 with	 appropriate	 mAbs.	 For	 cytokine	 and	620	
granzyme	 B	 analysis	 of	 human	 MAIT	 cells,	 PBMC	 obtained	 from	 fresh	 samples,	 were	621	
analyzed	after	stimulation	for	6	h	at	37°C	in	RPMI	medium	supplemented	with	10%	FCS	with	622	
PMA	 (25	 ng/ml)	 and	 ionomycin	 (1	 μg/ml),	 in	 the	 presence	 of	 Brefeldin	 A	 (10	 μg/ml).	 For	623	
cytokine	 staining	 of	mouse	 lymphocytes,	 cells	 were	 stimulated	with	 PMA	 (10	 ng/mL)	 and	624	
ionomycine	(1	µg/mL)	in	the	presence	of	Brefeldin	A	(10	µg/mL)	for	4	h	at	37°C	(all	reagents	625	
from	Sigma-Aldrich)	or	cells	were	stimulated	in	vivo	by	i.v.	injection	of	flagellin	(FLA-PA)	at	3	626	
μg/mouse	2	 h	 before	 analysis,	 as	 previously	 described
61
.	 After	 surface	 staining,	 cells	were	627	
fixed	and	permeabilized	with	Cytofix/Cytoperm	kit	 (BD	Biosciences)	washed	and	 incubated	628	
at	4°C	in	the	dark	for	30	min	with	anti-cytokines.		629	
	630	
24	
	
β-cell	 death	 induction	 by	 MAIT	 cells.	 EndoC-βH137	 was	 provided	 and	 cultured	 by	 R.	631	
Scharfmann	laboratory.	EndoC-βH1	were	platted	at	final	concentration	of	0.35	x	10
6	
cells/mL	632	
during	 24	 h	 in	 specifically	 formulated	 DMEM	media	 containing	 5.6	 mM	 glucose,	 2%	 BSA	633	
fraction	 V	 (Roche	 diagnostics),	 50	 μM	 2-mercaptoethanol,	 5	 μg/ml	 transferrin	 (Sigma-	634	
Aldrich),	 6.7	 ng/ml	 selenite	 (Sigma-Aldrich),	 100	U/mL	penicillin,	 100	μg/mL	 streptomycin.	635	
One	day	later,	when	indicated	cytokines	(TNF-α	1.100	U/mL,	IL-1β	1.000	U/mL,	IFN-γ	2.000	636	
U/mL)	were	added	in	EndoC-βH1	cultures	for	24	h.	In	parallel	MAIT	cells	from	donors	were	637	
purified	by	negative	isolation	with	Dynabeads	Goat	anti-Mouse	IgG	(Invitrogen),	then	stained	638	
with	 appropriate	 antibodies	 and	 sorted	 by	 FACS-ARIA.	 After	 sorting,	 MAIT	 cells	 were	639	
cultured	 in	complete	medium	containing	RPMI	supplemented	with	10%	FCS,	1%	penicillin/	640	
streptomycin,	 1%	HEPES	and	 supplemented	with	25	ng/mL	 recombinant	human	 IL-7	 (R&D	641	
Systems)	 for	 48	 h.	 Then,	 MAIT	 cells	 were	 added	 to	 EndoC-βH1	 cultures	 at	 1:1	 ratio	 and	642	
cultured	24	h	in	presence	of	different	concentrations	of	5-OP-RU.	Blocking	MR1	mAb	(26.5)	643	
was	added	when	indicated.	MAIT	cells	were	recovered	in	the	supernatants	and	analyzed	by	644	
flow	cytometry	for	their	surface	expression	of	CD25	and	CD107a.	Adherent EndoC-βH1	cells	645	
were	harvested	and	stained	with	APC	Annexin	V	Apoptosis	Detection	Kit	with	PI	(Biolegend)	646	
according	 to	 the	 manufacturer’s	 instruction.	 	 Cells	 were	 analyzed	 using	 LSRFortessa	647	
cytometer.		648	
	649	
Isolation	of	RNA	and	real-time	reverse	PCR	analysis.	Mouse	cells	were	 lysed	 in	RLT	buffer	650	
with	1%	β-mercaptoethanol,	and	mRNA	was	puriﬁed	from	lysed	cells	using	RNeasy	Mini	Kit	651	
(Qiagen).	 cDNA	 was	 produced	 using	 the	 Superscript	 III	 reverse	 transcriptase	 (Invitrogen).	652	
Quantitative-PCR	 analysis	 was	 performed	 with	 SYBR	 Green	 (Roche)	 and	 analyzed	 with	 a	653	
LightCycler	480	(Roche).	The	relative	expression	was	calculated	using	the	2
-∆∆Ct
	method	and	654	
normalized	 to	 the	 expression	 of	 the	 housekeeping	 gene	 GAPDH.	 The	 stability	 of	 GAPDH	655	
expression	was	confirmed	by	comparison	with	HPRT	mRNA.	The	primers	used	for	qPCR	are	656	
described	in	Supplementary	Table	5.	657	
	658	
MAIT	cell	transfer	experiment.	CD45.2	MAIT	cells	were	obtained	from	9-10	week-old	Vα19	659	
transgenic	 Cα-/-	 NOD	 mice.	 T	 cells	 were	 isolated	 from	 splenocytes,	 MLNs	 and	 PLNs	 by	660	
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depleting	 B	 cells,	 monocytes/macrophages,	 NK	 cells,	 dendritic	 cells,	 erythrocytes,	 and	661	
granulocytes	 using	Dynabeads	Untouched	Mouse	 T	 Cells	 kit	 (Invitrogen).	 These	 cells	were	662	
injected	i.v.	(4	x	10
6	
cells/mouse)	into	CD45.1	NOD	females	and	analyzed	several	days	later	663	
as	indicated.		664	
	665	
MAIT	cell	ligands	in	intestinal	content.	WT3-MR1+	cell	line,	provided	by	O.	Lantz,	was	used	666	
to	 detect	 5-OP-RU	 MAIT	 cells	 ligand	 from	 intestinal	 contents.	 Two	 hours	 before	 the	667	
experiment,	WT3-MR1+	cells	were	coated	onto	a	96-flat-well	plate	at	final	concentration	of	668	
0.5	 x	 10
6	
cells/mL	 in	 media	 containing	 DMEM	 Glutamax	 10%	 FBS,	 HEPES	 1M,	 sodium	669	
pyruvate	100	mM,	NeAA	1%	and	1%	penicillin/streptomycin.		Intestinal	content	from	colons	670	
were	recovered,	weighed	and	resuspended	 in	PBS.	Fecal	 supernatants	were	centrifuged	at	671	
14,000	rpm,	5	min,	at	4°C	and	passed	through	a	0.22	μM	filter.	Supernatants	were	tested	at	672	
final	concentration	of	0.7	mg	intestinal	content/mL.	Serial	dilutions	of	5-OP-RU	were	used	as	673	
positive	controls	and	acetyl-6-FP	was	added	to	determine	MR1-specific	activation.	MAIT	cells	674	
from	 the	 spleen	 of	 Vα19	 transgenic	 Cα-/-	 mice	 were	 purified	 by	 negative	 isolation	 with	675	
Dynabeads	Untouched	Mouse	T	Cells	kit	(Invitrogen)	and	co-cultured	O.N.	with	WT3-MR1+	676	
cells	at	final	concentration	of	5	x	10
5
	MAIT	cells/mL.	One	day	after,	MAIT	cells	were	stained	677	
with	appropriate	antibodies	and	activation	was	analyzed	by	flow	cytometry.		678	
	679	
Anti-islet	 T	 cell	 response.	 Cells	 from	 mouse	 pancreatic	 islets	 were	 recovered	 and	 then	680	
cultured	for	7	days	in	RPMI	medium	containing	10%	FCS,	1%	penicillin/	streptomycin	and	25	681	
U/mL	 of	 human	 rIL-2.	 To	 evaluate	 peptide-specific	 reactive	 T	 cells,	 single	 cell	 suspensions	682	
from	islet	culture	were	stimulated	for	5	h	with	IGRP206-214	peptide	(the	last	4	h	in	presence	683	
of	Brefeldin	A)	and	stained	with	CD45,	CD19,	TCRβ,	CD8	and	IFN-γ mAbs.	684	
	685	
In	vivo	analysis	of	intestinal	permeability.	Intestinal	permeability	was	determined	in	MR1-/-	686	
and	MR1+/-	 NOD	mice	 by	measuring	 the	 level	 of	 FITC-dextran	 in	 the	 blood.	 Briefly,	mice	687	
were	 water-starved	 overnight	 and	 in	 the	 morning,	 FITC-dextran	 (40	 kDa;	 Sigma)	 was	688	
administered	by	oral	gavages	(44	mg/100	g	body	weight).	Blood	was	collected	4	h	later	and	689	
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centrifuged	at	3000	g	for	20	min	at	4°C.	Plasma	(50	μL)	was	diluted	volume	to	volume	with	690	
PBS	 to	 determine	 fluorescence	 using	 a	 SPARK	 10M	 (TECAN).	 The	 concentration	 was	691	
determined	using	FITC-dextran	dilutions.	692	
	693	
Alcian	 blue	 staining	 and	 analysis.	 Intestinal	 sections	 (1	 cm	 in	 length)	 of	 ileum	 from	mice	694	
were	 collected	 and	 immediately	 fixed	 in	 4%	 paraformaldehyde	 PBS.	 Paraffin-embedded	695	
sections	 from	 ileum	were	 cut	 into	 4	 µm	 slices	 and	 stained	with	 Alcian	 blue	 periodic	 acid	696	
using	standard	techniques.	Slices	were	visualized	under	a	light	microscope	(Leica)	and	mean	697	
intensity	of	staining	were	evaluated	with	the	software	inForm	2.0.2	and	image	J.	698	
	699	
DNA	extraction	and	16S	rRNA	gene.	PLN	were	recovered	from	15-20	week-old	MR1-/-	and	700	
MR1+/-	 NOD	mice	 and	DNA	 extraction	was	 performed	 using	 DNeasy	 Blood	 and	 tissue	 Kit	701	
(QIAGEN)	 following	 the	 manufacturer’s	 instructions.	 Quantitative-PCR	 analysis	 was	702	
performed	 with	 SYBR	 Green	 (Roche)	 and	 analyzed	 with	 a	 LightCycler	 480	 (Roche).	 The	703	
relative	expression	was	calculated	using	the	2
-∆∆Ct
	methods	and	normalized	to	the	expression	704	
of	 the	 housekeeping	 gene	 GAPDH.	 The	 primers	 used	 for	 qPCR	 are	 described	 in	705	
Supplementary	Table	5.	The	PCR	products	were	sequenced	to	confirm	their	bacterial	origins.	706	
	707	
Statistical	analysis.	For	human	studies,	statistical	tests	between	two	groups	were	performed	708	
using	 two-tailed	Mann-Whitney	 test	 and	 signed-rank	Wilcoxon	 test	with	Graph	Pad	Prism.	709	
The	 Kruskal-Wallis	 test	 followed	 by	 the	Wilcoxon	 rank	 sum	 and	 the	 Spearman	 correlation	710	
test	was	 applied	 for	 all	 the	 correlation	 analysis	with	 Software	R.	 	 Corrections	 for	multiple	711	
testing	had	been	performed	on	the	human	results	when	we	compared	flow	cytometry	data	712	
between	the	three	groups	(the	children	with	recent	onset	T1D,	children	with	established	T1D	713	
and	 control	 children);	 Correction	 have	 well	 been	 applied	 after	 using	 the	 signed-rank	714	
Wilcoxon	test	with	an	adjustment	of	the	p-value	with	the	Holm	method	to	take	into	account	715	
the	 fact	 that	 multiple	 testing	 have	 been	 performed.	 A	 factorial	 discriminant	 analysis	 was	716	
performed	using	the	XLSTAT	2016	Software.	A	logistic	regression	model	was	fitted	with	the	717	
PROC	 CANDISC	 software	 (SAS	 version	 p.3)	 then	 a	 backward	 elimination	 procedure	 was	718	
applied.	 Prognostic	 validity	 of	 the	 model	 was	 evaluated	 by	 the	 receiver	 operating	719	
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characteristic	(ROC)	curve	analysis	and	measured	using	the	area	under	the	ROC	curve	(AUC).	720	
Statistical	analyses	were	performed	using	the	GraphPad	Prism	software	version	5.00.288	and	721	
the	 R	 software	 version	 3.2.3.	 For	 mouse	 studies,	 statistical	 analysis	 was	 performed	 with	722	
Prism	 software	 (Graph	 Pad)	 using	 nonparametric	 tests	 two-tailed	 Mann-Whitney	 or	723	
Student’s	 t-test,	 as	 appropriate.	 Diabetes	 incidence	was	 plotted	 according	 to	 the	 Kaplan–724	
Meier	method	and	 statistical	differences	between	groups	were	analyzed	using	 the	Gehan-725	
Breslow-Wilcoxon	test	or	the	log-rank	test.	P	values	were	considered	statistically	significant	726	
(*P<0.05,	**P<0.01,	***P<0.001).	727	
Figure	 1.	 Frequency	 and	 phenotype	 alterations	 of	 blood	MAIT	 cells	 from	 T1D	 children.	
MAIT	cells	were	analyzed	in	blood	from	children	with	recent	onset	T1D	(n=41),	children	with	
established	 T1D	 (n=23),	 as	 compared	 with	 control	 children	 (n=22).	 (a)	 Representative	
staining	 of	MAIT	 cells	 and	MAIT	 cell	 frequency	 among	 T	 lymphocytes.	 (b)	 Representative	
staining	and	frequency	of	MAIT	cells	expressing	different	cell	surface	molecules	(CCR6,	CD56,	
CD69,	CD25,	PD1)	 and	 intracellular	Bcl-2.	 P	 values	were	determined	by	Kruskal-Wallis	 test	
followed	 by	 the	 Wilcoxon	 rank	 sum	 test	 adjusted	 with	 the	 Holm	 method.	 (c)	 Multi-
parametric	analysis	of	 the	frequency	of	MAIT	cells	expressing	the	different	combination	of	
the	five	surface	molecules:	CCR6,	CD56,	CD25,	CD69	and	PD1.	Threshold	for	representation	
is	cell	frequency	>0.36%	of	MAIT	cells.	
	
Figure	 2.	 Functional	 alterations	 of	 blood	MAIT	 cells	 from	 T1D	 children.	MAIT	 cells	 were	
analyzed	in	blood	from	children	with	recent	onset	T1D	(n=25)	and	children	with	established	
T1D	 (n=18),	 as	 compared	 with	 control	 children	 (n=18).	 (a)	 Representative	 intracellular	
staining	 of	MAIT	 cells	 for	 cytokines	 and	GzB	 after	 PMA/ionomycin	 stimulation	 and	 graphs	
showing	 the	 frequency	 of	 MAIT	 cells	 producing	 cytokines	 and	 GzB.	 P	 values	 were	
determined	by	Kruskal-Wallis	test	followed	by	the	Wilcoxon	rank	sum	test	adjusted	with	the	
Holm	method.	 (b)	Multi-parametric	 analysis	of	 the	 frequency	of	MAIT	 cells	 expressing	 the	
different	combination	of	 the	 five	 intracellular	molecules:	GzB,	 IFN-γ,	TNF-α,	 IL-17	and	 IL-4.	
Threshold	for	representation	is	cell	frequency	>0.36%	of	MAIT	cells.	Note	that	data	for	IL-4	
are	 not	 shown	 because	 IL-4	 is	 expressed	with	 other	 cytokines	 and	 the	 frequency	 of	 each	
MAIT	 cell	 population	 expressing	 IL-4	 is	 >0.36%.	 (c)	Frequencies	 of	 CD69
+
	 and	 CD25
+
CD69
+
	
MAIT	cells	 from	children	controls	 (n=6)	and	children	with	recent	onset	T1D	(n=7)	after	ON	
stimulation	with	5-OP-RU	at	various	concentrations	(0	to	5	nmol/L).	Blocking	MR1	mAb	was	
added	when	indicated.	P	values	were	determined	by	Mann-Whitney	test.	
	
Figure	3.	Cytotoxic	function	of	MAIT	cells	on	human	β	cell	line.	(a)	Correlation	between	the	
age	of	children	with	recent	onset	T1D	(n=25)	at	diagnosis,	HbA1c	level	and	the	frequency	of	
blood	 MAIT	 cells	 expressing	 GzB	 after	 PMA/Ionomycin	 stimulation.	 P	 values	 were	
determined	 by	 Spearman	 test.	 (b)	 EndoC-βH1	 cells	 were	 cultured	 O.N.	 with	 or	 without	
cytokines.	Cells	were	stained	to	analyze	MR1	cell	surface	expression	by	flow	cytometry	(n=4)	
or	directly	lysated	to	analyze	the	relative	quantity	of	MR1	mRNA	by	RT	q-PCR	(n=7).	For	MR1	
cell	 surface	expression	MFI	±	SEM	was	 indicated	 for	each	groups	and	 for	q-PCR,	 statistical	
analysis	was	performed	by	 two-tailed	Mann	Whitney	 test,	P-value	was	 indicated	on	graph	
and	bar	represent	mean	±	SEM.	(c-e)	Induction	of	EndoC-βH1	cell	apoptosis	by	MAIT	cells	in	
co-culture	 in	presence	of	MAIT	cell	 ligand	(5-OP-RU).	MAIT	cells	 from	healthy	donors	were	
sorted	 and	 cultured	with	 IL-7	 during	 48h.	 EndoC-βH1	 cells	were	 cultured	with	 or	without	
cytokines	during	24h.	Then,	MAIT	cells	and	EndoC-βH1	cells	were	co-cultured	for	24h	at	1:1	
ratio	 with	 different	 doses	 of	 5-OP-RU.	 (c)	 Representative	 FACS	 plots	 of	 (d)	 EndoC-βH1	
apoptosis	by	MAIT	cells	at	different	doses	of	5-OP-RU	[0-1000	nmol/L]	(n=4).	Blocking	MR1	
mAb	 was	 added	 when	 indicated.	 Statistical	 analysis	 were	 performed	 by	 two-tailed	Mann	
Whitney	 test,	 P-values	were	 indicated	 on	 each	 graph	 and	 bar	 represent	mean	 ±	 SEM.	 (e)	
Activation	and	degranulation	of	MAIT	cells	in	presence	or	not	of	ligand	and	anti-MR1	(n=2).		
	
Figure	 4.	 MAIT	 cell	 characteristics	 in	 patients	 at	 different	 disease	 stages.	 (a)	 MAIT	 cell	
staining	of	 surface	and	 intracellular	molecules	performed	with	PBMC	from	fifteen	children	
with	 recent	 onset	 T1D	 at	 the	 time	 of	 diagnosis	 (on	 the	 left)	 and	 around	 one	 year	 after	
diabetes	onset	 (on	the	right).	P	values	were	determined	by	Signed-rank	Wilcoxon	Test.	 (b)	
Factorial	discriminant	analysis	based	on	the	expression	of	surface	and	intracellular	molecules	
by	MAIT	cells	from	the	children	with	recent	onset	T1D	(n=20),	the	children	with	established	
T1D	(n=15)	and	the	children	controls	(n=18).	(c)	ROC	Curve	of	the	predictive	model	defining	
the	 T1D	 phenotype.	 (d)	 FACS	 Analysis	 of	 MAIT	 cell	 frequency	 among	 T	 lymphocytes	 and	
frequency	 of	MAIT	 cells	 expressing	 different	 cell	 surface	molecules	 from	 frozen	 PBMC	 of	
adult	controls	(n=11)	and	adult	at	risk	T1D	donors	with	at	least	two	autoantibodies	(n=11).	P	
values	were	determined	by	Mann-Whitney	test.	
	
Figure	 5.	 Characterization	 of	 MAIT	 cells	 in	 NOD	 and	 C57BL/6	 mice.	 MAIT	 cells	 were	
identified	 using	 mouse	 MR1-5-OP-RU	 tetramer	 and	 MR1-Ac-6-FP	 tetramer	 was	 used	 as	
control.	MAIT	cells	are	defined	as	positive	MR1	tetramer	(5-OP-RU)	and	low	TCRβ	staining.	
Flow	 cytometric	 analysis	 of	 spleen,	 pancreatic	 lymph	 nodes	 (PLN),	 pancreatic	 islets	 and	
ileum	 from	C57BL/6	 and	NOD	mice	 at	 9-12	weeks	 of	 age.	 (a)	 Representative	 dot	 plots	 of	
MAIT	 cell	 staining	 and	 (b)	 frequencies	 and	 absolute	 numbers	 of	MAIT	 cells	 among	 TCRβ
+
	
leucocytes	.P	values	were	determined	by	two-tailed	Mann-Whitney	test	(statistical	analysis	
between	tissues	 from	NOD	mice;	C57BL/6	analyses	are	not	shown).	 (c)	Representative	dot	
plots	 of	 CD4	 and	 CD8	 expression	 by	MAIT	 cells	 in	 NOD	mice	 and	 (d)	 graphs	 showing	 the	
proportion	of	MAIT	cell	subsets	in	tissues	from	C57BL/6	and	NOD	mice.	Data	correspond	to	8	
mice	 from	three	 independent	experiments.	Bar	 represent	mean	±	SEM.	 (e)	Representative	
histograms	and	(f)	graphs	showing	CD69,	CD25	and	CD44	expression	on	MAIT	cells	from	NOD	
mice	 (white)	 and	C57BL/6	 (black).	P	 values	were	determined	by	 two-tailed	Mann-Whitney	
test	(statistical	analysis	between	tissues	from	NOD	mice;	C57BL/6	analyses	are	not	shown).	
(g)	Representative	dot	plots	and	(h)	graphs	showing	intracellular	cytokine	(IFN-γ,	TNF-α,	IL-
17A	and	 IL-22)	 staining	of	MAIT	 cells	 in	10	week-old	NOD	mice	 (white)	 and	C57BL/6	mice	
(black),	after	PMA/ionomycin	stimulation.		
	
Figure	6.	MAIT	 cell	 frequencies	and	 function	during	diabetes	development.	 (a)	MAIT	 cell	
frequency	 in	 different	 tissues	 from	 NOD	mice	 at	 three	 stages	 of	 disease	 development	 (6	
weeks,	 16	 weeks,	 and	 diabetic).	 For	 each	 tissue	 at	 least	 6	 mice	 per	 group	 from	 five	
independent	experiments	were	analyzed.	Statistics	were	performed	with	two	tailed	Mann-
Whitney	 test.	 (b)	 Purified	MAIT	 cells	 from	 CD45.2	 Vα19	 transgenic	 Cα-/-	 NOD	mice	were	
transferred	(i.v.)	into	CD45.1	NOD	mice	at	8-10	weeks	of	age	or	at	22-25	weeks	of	age	(4.5	
10
6
	 cells/mice).	 At	 day	 5	 after	 transfer,	 mice	 were	 sacrificed	 and	 islets	 and	 ileum	 were	
analyzed.	 Graphs	 and	 representative	 plots	 of	 the	 frequency	 and	 the	 absolute	 number	 of	
transferred	MAIT	cells	are	shown.	(c-d)	Graphs	showing	the	relative	quantity	of	(c)	GzB,	IFN-γ	
transcripts	 in	MAIT	cells	 from	pancreatic	 islets	and	(d)	 IL-22	and	IL-17A	transcripts	 in	MAIT	
cells	from	ileum	at	three	stages	of	disease	development.	Each	symbol	represents	a	pool	of	
two	mice	and	data	were	obtained	in	two	independent	experiments.	Bars	represent	mean	±	
SEM.	 (e-f)	Cytokine	 intracellular	staining	after	 in	vitro	PMA/ionomycin	stimulation	(e)	or	 in	
vivo	 flagellin	stimulation	 (f)	of	MAIT	cells	and	conventional	αβT	cells	 from	pre-diabetic	 (17	
weeks)	and	diabetic	mice;	(e)	GzB	and	IFN-γ	for	islets	and	(f)	IL-17A	and	IL-22	for	ileum.	Dot	
plots	are	representative	of	two	independent	experiments,	with	a	total	of	6	mice	per	group.		
	
Figure	7.	Gut	mucosa	alterations	during	T1D	progression	in	NOD	mice.	(a)	Representative	
dot	 plots	 of	 RORγt–GFP	 expression	 by	 MAIT	 cells;	 representative	 histogram	 and	 graph	
showing	MFI	of	RORγt–GFP
+	
MAIT	cells	at	three	stages	of	disease	development.	Data	were	
pooled	 from	 two	 independent	 experiments.	 (b)	 Cells	 of	 ileal	 tissue	 from	 NOD	mice	 were	
obtained	 and	 analyzed	 by	 RT-qPCR	 at	 two	 stages	 of	 the	 disease	 (10	 weeks	 and	 diabetic	
mice);	 the	 relative	 quantity	 of	 IL-23	 transcript	 is	 shown.	 Data	 are	 pooled	 from	 two	
independent	 experiments.	 (c)	 Intestinal	 gut	 permeability	 was	 measured	 by	 in	 vivo	 FITC-
dextran	assay	 in	NOD	mice	at	 two	stages	of	 the	disease	 (10	weeks	and	diabetic).	Data	are	
representative	of	three	independent	experiments.	(d-e)	Representative	FACS	plots	and	dose	
response	of	MAIT	cell	activation	after	 in	presence	of	WT3-	MR1,	with	different	doses	of	5-
OP-RU	ligand	and	in	presence	or	absence	of	acetyl-6-FP	inhibitor	ligand	at	10µM.		(d-f)	MAIT	
cells	were	activated	by	fecal	supernatants	in	an	MR1-dependent	manner.	The	dose	response	
of	MAIT	cells	activation	with	different	 concentrations	of	 fecal	 supernatants	 in	presence	or	
absence	of	acetyl-6-FP	inhibitor	ligand	(n=16)	is	shown.	(g)	Activation	of	purified	MAIT	cells	
by	fecal	supernatant	from	NOD	mice	at	different	stages	of	disease	development.	Data	were	
pooled	from	three	independent	experiments.	All	statistical	analyses	were	performed	by	two-
tailed	Mann	Whitney	test,	P-value	were	indicated	on	each	graph	and	bar	represent	mean	±	
SEM.	
	
Figure	 8.	MAIT	 cell	 deficiency	 exacerbates	 diabetes	 development	 and	 alters	 gut	mucosa	
integrity.	 All	 analyses	 were	 performed	 on	 co-housed	 MR1
-/-
	 and	 MR1
+/-
	 NOD	 female	
littermates.	 (a)	 Representive	 dot	 plots	 of	 T	 cell	 staining	 with	 MR1-5-OP-RU	 and	 CD1d-α-
Galactosyl	 Ceramide	 tetramers	 of	 splenic	 cells,	 gated	 on	αβT	 cells.	 Numbers	 indicate	 the	
percentage	of	MAIT	and	 iNKT	cells	among	TCRβ cells.	 (b)	Diabetes	 incidence	of	MR1-/-	and	
MR1
+/-
	 mice	 (n=30	 and	 32	 respectively);	 P	 values	 were	 determined	 by	 Gehan-Breslow-
Wilcoxon	 test.	 (c)	 Representative	 dot	 plots	 and	 graphs	 showing	 percentage	 of	 IGRP206-214	
tetramer	 positive	 cells	 among	 TCRβ+	 and	 CD8+	 T	 cells.	 (d)	 Frequency	 of	 IFN-γ+ IGRP206-214	
specific	CD8
	
T	cells	from	pancreatic	islets	after	culture.	(e)	Analysis	of	CD11c
+
CD11b
+
CD103
+
	
dendritic	 cells	 from	 ileum,	 mesenteric	 (MLN)	 and	 pancreatic	 lymph	 nodes	 (PLN).	
Representative	flow	cytometry	dots	showing	the	gating	strategy,	MHC	class	II	staining,	and	
graphs	 showing	 the	 absolute	 numbers	 of	 this	 DC	 subset,	 the	 frequencies	 and	 absolute	
numbers	 of	 this	 DC	 subset	 expressing	 CD86	 and	 MHC	 class	 II.	 (f)	 Intestinal	 permeability	
measured	 by	 FITC-dextran	 assay.	 (g)	 Occludin,	 mucin-2	 and	 claudin-4	 mRNA	 levels	 in	
epithelial	cells	 from	ileum.	 (h)	Representative	photographs	of	Alcian	blue	staining	of	 ileum	
section	 and	 graph	 showing	 the	mean	 intensity	 of	 the	 staining	 in	Goblet	 cells.	 (i)	 Absolute	
numbers	 of	 lymphocytes	 infiltrating	 lamina	 propria.	 (j)	DNA	 from	 PLN	was	 extracted	 and	
then	the	relative	quantity	of	16S	bacterial	DNA	was	analyzed	by	qPCR.	For	graphs	a	and	c-j,	
analyses	were	performed	on	15	week-old	mice,	each	point	represents	an	individual	mouse,	
data	were	pooled	from	two	or	three	independent	experiments,	P	values	were	determined	by	
Mann-Whitney	test.	Bars	represent	mean	±	SEM.	
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Supplementary	Figure	1	(a)	Number	of	blood	MAIT	cells	among	ﬁve	millions	of	PBCM	from	children	with	recent	
onset	T1D	(n=35),	children	with	established	T1D	(n=23)	as	compared	with	control	children	(n=22).	(b)	Frequency	
of	 the	 subpopulaNon	 CD8+	 and	 DN	 MAIT	 cells	 among	 T	 lymphocytes	 from	 children	 with	 recent	 onset	 T1D	
(n=41),	 children	 with	 established	 T1D	 (n=23)	 as	 compared	 with	 control	 children	 (n=22).	 P	 values	 were	
determined	by	Kruskal-Wallis	test	followed	by	the	Wilcoxon	rank	sum	test	adjusted	with	the	Holm	method.		
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Supplementary	Figure	2	 (a)	Frequency	of	Vα7.2+CD161-	cells	among	T	 lymphocytes	and	 (b)	 frequency	of	 the	
CD4+	and	CD8+	T	lymphocytes	from	children	with	recent	onset	T1D	(n=41),	children	with	established	T1D	(n=23)	
as	 compared	 with	 control	 children	 (n=22).	 No	 signiﬁcaNve	 diﬀerences	 as	 determined	 by	 Kruskal-Wallis	 test	
followed	by	the	Wilcoxon	rank	sum	test	adjusted	with	the	Holm	method.		
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Supplementary	Figure	3	(a)	CorrelaNon	between	frequency	of	MAIT	cells	expressing	CCR6	and	frequency	of	MAIT	cells	
among	T	 lymphocytes	from	children	with	recent	onset	T1D	(n=41).	(b)	CorrelaNon	between	frequency	of	MAIT	cells	
expressing	Bcl-2	and	frequency	of	MAIT	cells	among	T	lymphocytes	from	children	with	recent	onset	T1D	(n=15).	Less	
samples	were	analyzed	for	Bcl-2	staining	due	to	limited	number	of	PBMC.	(c)	CorrelaNon	between	frequency	of	MAIT	
cells	expressing	CD25	and	frequency	of	MAIT	cells	among	T	lymphocytes	from	children	with	recent	onset	T1D	(n=35).	
CorrelaNon	 between	 frequency	 of	 MAIT	 cells	 expressing	 CD25	 and	 frequency	 of	 MAIT	 cells	 expressing	 PD1	 from	
children	with	recent	onset	T1D	(n=35).	P	values	were	determined	by	Spearman	test.	
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Supplementary	 Figure	 4	CorrelaNon	 between	 frequency	 of	MAIT	 cells	 expressing	GzB	 and	 frequency	 of	MAIT	 cells	
among	 T	 lymphocytes	 from	 children	 with	 recent	 onset	 T1D	 (n=22).	 CorrelaNon	 between	 frequency	 of	 MAIT	 cells	
expressing	CCR6	and	frequency	of	MAIT	cells	expressing	GzB	(n=22).	P	values	were	determined	by	Spearman	test.	
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Supplementary	Figure	5	CorrelaNon	between	frequency	of	MAIT	cells	expressing	diﬀerent	surface	and	intracellular	
molecules	and	the	age	of	the	children	with	recent	onset	T1D	at	the	diagnosis.	For	surface	staining	n=41	and	Bcl-2	
analysis	n=16.	P	values	were	determined	by	Spearman	test.	
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Supplementary	 Figure	5	Frequency	of	MAIT	 cells	 among	T	 lymphocytes	 and	 frequency	of	MAIT	 cells	 expressing	
surface	molecules	aaer	staining	on	frozen	PBMC	from	children	with	recent	onset	T1D		(n=20)	and	control	children	
(n=12).	P	values	were	determined	by	Mann-Whitney	Test.		
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Supplementary	 Figure	 6.	 CD44	 expression	 on	 MAIT	 cell	 subsets	 in	 NOD	 and	 C57BL/6	 mice.	 (a)	 RepresentaNve	
histogram	of	 CD44	expression	on	CD4	 (blue),	 CD8	 (orange)	 and	DN	 (red)	 subsets	 of	MAIT	 cells	 from	 spleen,	 PLNs,	
islets	and	ileum	from	NOD	mice.	(b)	Percentage	of	CD44+	MAIT	cells	in	each	subset	of	diﬀerent	Nssues	from	10	week-
old	NOD	and	C57BL/6	mice.	Bars	graphs	depict	mean	±	SEM	from	at	least	8	mice,	analyzed	in	four	(NOD	mice)	or	two	
(C57BL/6)	separate	experiments.	
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Supplementary	Figure	7.	Comparison	of	acNvaNon	markers	on	MAIT	cells	between	NOD	and	C56BL/6	mice.		
Frequency	of	CD69+,	CD25+	and	CD44+	MAIT	cells	from	the	spleen,	PLNs	and	ileum	from	10	week-old	NOD	
(white)	and	C57BL/6	(black)	mice.	All	data	are	representaNve	of,	at	least,	two	separate	experiments	and	each	
point	represents	a	pull	of	two	mice.		
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Supplementary	Figure	8.	Cytokine	producNon	by	MAIT	cells	in	NOD	mice.	RepresentaNve	dot	plots	showing	intracellular	
cytokine	 staining	 of	MAIT	 cells	 from	 islets	 and	 ileum	 of	 10	week-old	 NOD	mice.	MAIT	 cells	 are	 analyzed	 aaer	 PMA/
ionomycin	sNmulaNon	and	labeled	with	MR1-5-OP-RU	tetramer	and	then	ﬁxed	and	permeabilized	before	staining	with	
IL-17,	 IL-22,	 TNF-α,	 IFN-γ	mAbs.	ConvenNonal	αβT	 cells	 are	 also	 analyzed	as	 control.	Data	 are	 representaNve	of	 three	
experiments	with	combined	total	of	9	mice.			
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Supplementary	 Figure	 9.	MAIT	 cell	 expression	 of	 PLZF,	 ROR-γt	 and	 T-bet.	 Expression	 of	 the	 transcripNon	 factors	
PLZF,	ROR-γt	and	T-bet	by	MAIT	cells	from	the	spleen,	PLNs,	pancreaNc	islets	and	ileum	from	10	week-old	NOD	mice.	
RepresentaNve	dot	plots	with	indicated	percentage	of	PLZF,	ROR-γt	and	T-bet	expression	in	MAIT	and	iNKT	cells	from	
diﬀerent	 Nssues.	 Dot	 plots	 for	 each	marker	 show	 data	 concatenated	 from	 two	 or	 three	 individual	mouse	 Nssue	
samples	from	one	experiment.	Data	are	representaNve	of	two	similar	experiments.	FMO,	ﬂuorescence	minus	one.	
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Supplementary	 Figure	 10.	 Analysis	 of	 T	 cell	 populaNons	 in	 MR1-/-	 and	 MR1+/-	 NOD	 mice.	 Graphs	
showing	the	frequency	of	convenNonal	CD4	and	CD8	T	cells,	Foxp3	Treg	cells,	Foxp3-	CD25+	CD4+	T	cells,	
iNKT	cells	and	γδT	cells	in	PLNs	and	ileum	as	determined	by	ﬂow	cytometry.	Analysis	was	performed	on	
8-12	mice	per	groups,	in	two	independent	experiments.	P	values	were	determined	with	Mann-Whitney	
test	and	bar	represent	mean	±	s.e.m).		
Supplementary	Figure	11.	GeneraNon	of	MR1-/+	NOD	mice.	(a)	SchemaNc	diagram	of	mouse	chromosome	1,	mr1	
gene	and	insulin	dependent	diabetes	(Idd)	5.4a	and	b	loci.	(b)	CumulaNve	incidence	of	diabetes	of	NOD	(n=23)	and	
MR1+/-	NOD	(n=32)	mice.	StaNsNcal	analysis	was	performed	with	Log	rank-test.	
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Supplementary	Figure	12.	SchemaNc	view	of	the	dual	role	of	MAIT	cells	in	the	physiopathology	of	
type	 1	 diabetes.	 MAIT	 cells	 recognize	 bacterial	 metabolites	 and	 changes	 of	 gut	 microbiota	 are	
associated	with	diabetes	development.	 In	 the	 intesNne	of	10	week-old	NOD	 females,	MAIT	 cells	
produce	IL-17A	and	IL-22,	two	key	cytokines	involved	in	the	maintenance	of	gut	mucosa	integrity.	
(1)	 During	 disease	 progression,	 the	 producNon	 of	 both	 cytokines	 by	 ileal	 MAIT	 cell	 decreases,	
thereby	 dampening	 their	 protecNve	 role.	 (2)	Moreover	 in	MR1-/-	 NOD	mice	 lacking	MAIT	 cells	
several	abnormaliNes	are	observed	in	the	gut	mucosa:	increased	gut	permeability,	decreased	Nght	
juncNon	 protein	 expression,	 alteraNon	 of	 mucus	 producNon	 and	 distribuNon,	 and	 increased	
lymphocyte	 inﬁltraNon	 in	 the	 lamina	propria.	 (3)	This	defecNve	 intesNnal	barrier	 could	 favor	 the	
translocaNon	of	 bacterial	 ligands	 such	 as	 lipopolysaccharide	 (LPS),	DNA,	 pepNdoglycan	 (PG)	 that	
could	 promote	 dendriNc	 cell	 acNvaNon	 as	 evidenced	 by	 their	 increase	 MHC	 class	 II	 and	 CD86	
upregulaNon	 in	 pancreaNc	 lymph	nodes.	 (4)	 Subsequently,	 these	DC	 can	 acNvate	 autoreacNve	 T	
cells	recognizing	beta-cell	anNgen.	(5)	These	anN-islet	T	cells	migrate	to	the	pancreas	where	they	
produce	IFN-g	and	thus	destroy	beta	cells.	This	mechanism	highlights	the	protecNve	role	of	MAIT	
cells	 against	 T1D	 development.	 (6)	 However,	 MAIT	 cells	 can	 also	 parNcipate	 to	 beta-cell	 death	
through	their	producNon	of	IFN-g	and	granzyme	B	(GzB).	(7)	InteresNngly,	in	T1D	paNents	there	is	
an	increase	producNon	of	GzB	by	blood	MAIT	cells.	While	MAIT	cells	exert	dual	funcNon,	analysis	of	
mouse	models	reveal	the	dominant	protecNve	role	of	MAIT	cells	in	T1D.	
		
